emt和igf审审1r表达与吉非替尼二线治疗晚期非小细胞肺癌疗效关系word格式论文.docx

analysized in order to explore the effect of the expression of EMT and IGF-1R on the efficacy of gefitinib and overall survival.Results:The positive rate of IGF-1R,E-cadherin and Vimentin in 76 patients was 64.5%,46.1% and 53.9%,respectively. The EMT was not correlated with clinicopathological characteristics.However,the IGF-1R expression was related to histological types.The positive rate of IGF-1R was significantly higher in the non-adrenocarcinoma patients than that in adrenocarcinoma patients[22/28(78.5%) VS 27/48(56.2%)].A slight but statistical significant correlation was found between EMTand IGF-1R（r=0.252，P=0.028）.The EMT(-) was more frequently observed in thepatients with EGFR mutation.However,the expression of IGF-1R was not associated with EGFR mutation status.Both DCR and ORR in EMT(-) patients were significantly higher than that in EMT(+) patients(DCR:65.7% versus 24.3%.p0.05;ORR:37.1% versus 9.8%,p0.05),and also were significantly higher in IGF-1R(-) patients than that in IGF-1R(+) patients(DCR:66.7% versus 30.6%,p0.05;ORR:37.0% versus 14.3%,p0.05).The EMT(-) patients had a signif icantly longer median overall survival (10.0 months vs. 5.0 months,p0.05) . The median overall survival was 8.0 months in the IGF-1R(-) patients and 5.0 months in the IGF-1R(+) patients(p0.05) In the patients with EGFR mutations,the EMT(-) patients showed relative hogher ORR than EMT(+) patients.In the patients with wild-type EGFR,the highest ORR was found in those with both EMT(-) and IGF-1R(-)Conclusion: EMT and the expression of IGF-1R might be associated with the efficacy of gefitinib,and may be one of the predictive factors for efficacy of gefitinib as the second line therapy for advanced NSCLC.[Key words]Epithelial-Mesenchymal Transition；IGF Type 1 Receptor；Gefitinib；Non-Small-Cell Lung Cancer广州医学院学位论文原创性声明本人郑重声明：所呈交的论文是本人在导师的指导下独立进行研究所取得的 研究成果。文中依法引用他人的成果、对本文的研究作出重要贡献的个人和集体， 均已在文中做出明确标注或得到许可。论文内容未包含法律意义上已属于他人的 任何形式的研究成果，也不包括本人已用于其他学位申请的论文或成果。本人如违反上述声明，愿意承担以下责任和后果： 1．交回